SCHEMBL5651088

SCHEMBL5651088

CCN(CC)CCCNC(=O)c1ccc(-c2nc3ncccc3[nH]2)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.52
PDE5A O76074 11/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 1/20 0.51
PDE3B Q13370 1/20 0.51
PDE3A Q14432 1/20 0.51
HSD17B10 Q99714 1/20 0.51
PRMT5 O14744 1/20 0.49
WDR77 Q9BQA1 1/20 0.49
AURKA O14965 1/20 0.48
HTT P42858 1/20 0.47
PDE4A P27815 4/20 0.45
PDE4B Q07343 4/20 0.45
PDE4C Q08493 4/20 0.45
PDE4D Q08499 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647604 0.89 TSHR (0.44) PDE5AKDM4EALDH1A1HPGDKMT2A
SCHEMBL5654376 0.88 TSHR (0.43) PDE5AKDM4EALDH1A1HPGDKMT2A
SCHEMBL5648995 0.86 PRMT5 (0.49) KDM4EHSD17B10PRMT5WDR77HTT
SCHEMBL5653023 0.83 PRMT5 (0.50) KMT2APRMT5WDR77HTTTMEM97
SCHEMBL5651233 0.82 FLT3 (0.54) KDM4EALDH1A1LMNAHPGDKMT2A
SCHEMBL5650247 0.82 PRSS12 (0.50) PRMT5WDR77HTTTMEM97SIGMAR1
SCHEMBL5651251 0.82 PRMT5 (0.50) KDM4EMEN1ALDH1A1LMNACYP1A2
SCHEMBL5651548 0.81 PDE5A (0.54) PDE2APDE5AKDM4EMEN1ALDH1A1
SCHEMBL10746239 0.81 PDE2A (0.65) PDE2APDE5AKDM4EMEN1ALDH1A1
SCHEMBL5653271 0.81 CYP2D6 (0.61) PDE2APDE5AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PDE2A 2744/4885PDE5A 3793/4885KDM4E 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.